Clik here to view.
Tyra Biosciences gives a first look at its challenge to J&J’s targeted...
Tyra Biosciences unveiled early trial results on its FGFR3-specific inhibitor in advanced bladder cancer patients on Friday, the public company’s first presentation of human data since its inception in...
View ArticleWhy are Lilly and Roche trying to block Novo's deal for Catalent?
This week, Roche joined Eli Lilly in coming out against a deal that would add significant new manufacturing capacity to Novo Nordisk, to help it meet some of the huge demand for its GLP-1 drugs Wegovy...
View ArticleClik here to view.
New radiopharma spinout Rhine Pharma banks on one trial for success, Telix...
The future of Telix Pharmaceuticals’ new spinout Rhine Pharma hinges on the outcome of one early-stage trial, Telix CEO Christian Behrenbruch told Endpoints News in an interview. Christian Behrenbruch...
View ArticleClik here to view.
FDA approves new type of oral antibiotic for UTIs
The FDA has cleared Iterum’s oral antibiotic for certain patients with uncomplicated urinary tract infections (uUTIs) who have limited or no alternative oral options. Orlynvah, also known as oral...
View ArticleHouse Republicans push for more transparency on government-funded trial data
A group of four Republicans on the House Committee on Energy and Commerce called for more transparency of clinical trial data funded by taxpayers after a New York Times story ran this week that said an...
View ArticleHungary's Olivér Várhelyi readies to be EU health commissioner, pledging...
On the heels of her reelection in July, European Commission President Ursula von der Leyen tasked her new commissioner-designate for health and animal welfare with a full plate of pharma-related...
View ArticleRevolution Medicines breaks ground in challenging pancreatic cancer with two...
In an interview Friday, Revolution Medicines CEO Mark Goldsmith, who says he prefers to understate rather than exaggerate, floated a lofty goal: cure pancreatic cancer — or get close. “That’s our aim,...
View ArticleLatest salvo in Pfizer activist fight; John Carroll's Q3 biotech roundup;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleHow Nvidia plans to provide the building blocks of AI in health tech
LAS VEGAS — Nvidia’s ambitions within healthcare have a strong foothold in biopharma and life sciences. It’s now looking to grow its presence in digital health. The AI chipmaker’s healthcare strategy...
View ArticleIambic attempts to ‘break the wall’ between the lab and clinic with new AI model
Iambic Therapeutics has used its AI models to build a pipeline and put its first drug candidate in the clinic earlier this year. Now, the San Diego company is debuting a model with even bolder ...
View ArticleNovartis takes $800M MorphoSys writedown mere months after closing acquisition
Just five months after closing its $2.9 billion deal for MorphoSys, Novartis has recorded an $800 million impairment on the acquisition after a review of “certain clinical trial data,” the company said...
View ArticleCorrected: Genmab lines up T cell engager pact with Revitope
Genmab, a well-known Danish antibody biotech, is partnering with Revitope Oncology on T cell engagers, a type of cancer medicine that has become more popular this year and is now being tested in...
View ArticlePfizer raises revenue guidance by $1.5B amid activist pressure
Pfizer hasn’t escaped the volatility of its Covid-19 business — for better or worse. Making its first substantive comments on the activist investor pushing for changes at the company, Pfizer on Tuesday...
View ArticleParagon launches another company in hot PD-1xVEGF space that goes straight to...
Antibody maker Paragon Therapeutics has formed another company, this time in the bustling cancer space of PD-1xVEGF, and it will go straight onto the public markets. The new biotech, named Crescent...
View ArticlePathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AI
Chicago startup Pathos AI has completed a $62 million Series C to keep looking for Phase 1 cancer drugs that it can acquire and test in more specific patient populations, it
View ArticleGLP-1 compounding pharmacies took center stage at digital health’s biggest...
LAS VEGAS — The hottest companies at this year's annual HLTH conference weren't buzzy startups with billions in backing for a new approach to disrupt the healthcare industry. They were compounding...
View ArticleEyepoint sells $100M in shares after unveiling eye disease data for...
EyePoint Pharmaceuticals is selling $100 million worth of shares on the back of positive mid-stage data for a drug-device candidate in diabetic macular edema. The results pushed its share price up by...
View ArticleGSK buys autoimmune T cell engager for $300M upfront from Chimagen
As early data show how T cell engagers — originally developed for cancers — can potentially treat a range of autoimmune diseases, GSK is buying its own molecule from Chimagen Biosciences. The UK pharma...
View ArticleTwo type 1 diabetes patients are insulin-free after Eledon's...
Eledon Pharmaceuticals’ experimental immunosuppressant helped two patients with type 1 diabetes go insulin-free following an islet cell transplant, the company announced Tuesday. The company's stock...
View ArticleVera’s $300M offering; Abeona resubmits treatment for rare skin disease
Plus, news about Astellas, Clover, ElevateBio, Monopar, Idorsia and Neurocrine Biosciences: Vera Therapeutics plans $300M offering: The California biotech is selling shares after presenting Phase 2b...
View Article